RVL Pharmaceuticals plc Quarterly Operating Income (Loss) in USD from Q3 2017 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RVL Pharmaceuticals plc quarterly/annual Operating Income (Loss) history and growth rate from Q3 2017 to Q2 2023.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the quarter ending June 30, 2023 was -$22M, a 45.6% decline year-over-year.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the twelve months ending June 30, 2023 was -$70.8M, a 1.36% decline year-over-year.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2022 was -$59M, a 28.7% increase from 2021.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2021 was -$82.8M, a 8.71% increase from 2020.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2020 was -$90.7M, a 29% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$70.8M -$22M -$6.9M -45.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$63.9M -$10.3M -$4.9M -90.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$59M -$24.5M -$404K -1.67% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-20
Q3 2022 -$58.6M -$13.9M +$11.2M +44.7% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$69.8M -$15.1M +$5.05M +25% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$74.9M -$5.4M +$7.87M +59.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$82.8M -$24.1M +$51.8M +68.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$135M -$25.2M -$26.6M -1864% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$108M -$20.2M -$2.86M -16.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$105M -$13.3M -$14.5M -1210% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$90.7M -$76M -$206M -158% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $116M $1.43M +$124M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$8.63M -$17.3M +$114M +86.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$123M $1.2M +$4.69M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$128M $130M +$238M Oct 1, 2019 Dec 31, 2019 8-K 2021-09-08
Q3 2019 -$366M -$123M -$120M -4629% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$245M -$132M -$144M -1142% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$101M -$3.5M -$2.4M -219% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$98.5M -$107M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-19
Q3 2018 -$2.6M +$15.6M +85.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $12.6M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$1.1M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q3 2017 -$18.2M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.